Danqi Piantang Jiaonang (DJ), a Traditional Chinese Medicine, in Poststroke Recovery

Chen, Christopher; Venketasubramanian, Narayanaswamy; Gan, Robert N.; Lambert, Caroline; Picard, D; Chan, Bernard P.L.; Chan, Edwin; Bousser, Marie Germaine; Shi, Xuemin

doi:10.1161/strokeaha.108.531616

Cited by 91 publications

(91 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is consistent with previously published studies on MLC601, which detected improved functional outcomes and motor recovery among mainly nonacute ischemic stroke patients. 11,12,14 These findings support the possible neurorestorative effects of MLC601 and would be topics of interest for further nonclinical and clinical investigations.…”

Section: Discussionsupporting

confidence: 55%

“…Because previous studies on MLC601 suggested a benefit in nonacute ischemic stroke patients, [11][12][13][14][15][16][17] the time window of 72 hours was chosen for this study in an attempt to test both the neuroprotective and neurorestorative properties of MLC601.…”

Section: Discussionmentioning

confidence: 99%

“…[8][9][10] Initial clinical studies on patients who were 2 weeks to 6 months after index stroke showed MLC601 improved recovery in terms of functional outcome and neurological disability. 11 More studies have since been published assessing the benefit and safety of MLC601 in nonacute stroke patients using different clinical outcomes. [12][13][14][15][16][17][18][19] Although most patients experience some spontaneous recovery in the months after a stroke, the degree and timing of recovery are variable.…”

Section: August 2013mentioning

confidence: 99%

“…[11][12][13][14][15][16][17][18] MLC601 and matching placebo were provided by Moleac (Singapore). Each 400 mg MLC601 capsule contains 9 herbal components (extracts derived from raw herbs consisting of Radix astragali, Radix salviae miltorrhizae, Radix paeoniae rubra, Rhizoma chuanxiong, Radix angelicae sinensis, Carthamus tinctorius, Prunus persica, Radix polygalae, and Rhizoma acori tatarinowii) and 5 animal components (Hirudo, Eupolyphaga seu steleophaga, Calculus bovis artifactus, Buthus martensii, and Cornu saigae tataricae).…”

Section: Study Treatmentmentioning

confidence: 99%

See 3 more Smart Citations

Chinese Medicine Neuroaid Efficacy on Stroke Recovery

Chen

Young²,

Gan³

et al. 2013

Stroke

Self Cite

View full text Add to dashboard Cite

Background and Purpose— Previous clinical studies suggested benefit for poststroke recovery when MLC601 was administered between 2 weeks and 6 months of stroke onset. The Chinese Medicine Neuroaid Efficacy on Stroke recovery (CHIMES) study tested the hypothesis that MLC601 is superior to placebo in acute, moderately severe ischemic stroke within a 72-hour time window. Methods— This multicenter, double-blind, placebo-controlled trial randomized 1100 patients with a National Institutes of Health Stroke Scale score 6 to 14, within 72 hours of onset, to trial medications for 3 months. The primary outcome was a shift in the modified Rankin Scale. Secondary outcomes were modified Rankin Scale dichotomy, National Institutes of Health Stroke Scale improvement, difference in National Institutes of Health Stroke Scale total and motor scores, Barthel index, and mini-mental state examination. Planned subgroup analyses were performed according to age, sex, time to first dose, baseline National Institutes of Health Stroke Scale, presence of cortical signs, and antiplatelet use. Results— The modified Rankin Scale shift analysis–adjusted odds ratio was 1.09 (95% confidence interval, 0.86–1.32). Statistical difference was not detected between the treatment groups for any of the secondary outcomes. Subgroup analyses showed no statistical heterogeneity for the primary outcome; however, a trend toward benefit in the subgroup receiving treatment beyond 48 hours from stroke onset was noted. Serious and nonserious adverse events rates were similar between the 2 groups. Conclusions— MLC601 is statistically no better than placebo in improving outcomes at 3 months when used among patients with acute ischemic stroke of intermediate severity. Longer treatment duration and follow-up of participants with treatment initiated after 48 hours may be considered in future studies. Clinical Trial Registration— URL: http://www.clinicaltrials.gov . Unique identifier: NCT00554723.

show abstract

Section: Discussionsupporting

confidence: 55%

Section: Discussionmentioning

confidence: 99%

Section: August 2013mentioning

confidence: 99%

Section: Study Treatmentmentioning

confidence: 99%

See 2 more Smart Citations

Chinese Medicine Neuroaid Efficacy on Stroke Recovery

Chen

Young²,

Gan³

et al. 2013

Stroke

Self Cite

View full text Add to dashboard Cite

show abstract

“…Previous clinical studies performed in China have shown that Neuroaid enhances stroke patients’ recovery from their neurological disability and improves functional outcome and thus, may be beneficial in post-stroke rehabilitation [7]. However, these trials did not comply with the International Conference on Harmonization/Good Clinical Practice guidelines and used positive controls.…”

Section: Introductionmentioning

confidence: 99%

A Double-Blind, Placebo-Controlled, Randomized Phase II Pilot Study to Investigate the Potential Efficacy of the Traditional Chinese Medicine Neuroaid (MLC 601) in Enhancing Recovery after Stroke (TIERS)

Kong

Wee

et al. 2009

Cerebrovasc Dis

Self Cite

View full text Add to dashboard Cite

Background and Objective: Previous clinical studies have shown that Neuroaid (MLC 601) may be beneficial in post-stroke rehabilitation. Our aim was to investigate the efficacy of Neuroaid on motor recovery in ischemic stroke patients using rehabilitation endpoints in accordance with the International Conference on Harmonization/Good Clinical Practice guidelines, in order to provide predictive information for further larger trials. Methods:This is a phase II double-blind, placebo-controlled pilot study of 40 subjects admitted with a recent (less than 1 month) ischemic stroke. All subjects were given either Neuroaid or placebo, 4 capsules 3 times a day for 4 weeks. Fugl-Meyer Assessment (FMA), National Institutes of Health Stroke Scale and Functional Independence Measure scores were measured at initiation of the treatment, and at 4 and 8 weeks. Results: None of the outcomes was statistically significant between the two groups. However, FMA scores showed a positive trend for improvement with Neuroaid treatment over time. Subgroup analysis of subjects with posterior circulation infarction and severe stroke both showed a tendency for better recovery. Conclusion: Some positive trends were observed in the Neuroaid group. A larger multicenter trial focusing on severe stroke patients is needed to better evaluate the role of Neuroaid in aiding stroke recovery in rehabilitation.

show abstract